Skip to search formSkip to main contentSkip to account menu

response to irinotecan

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer
Diversity in colorectal cancer biology is associated with variable responses to standard chemotherapy. We aimed to identify and… 
2015
2015
ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer
Background: Active efflux of irinotecan by ATP-binding cassette (ABC)-transporters, in particular ABCB1 and ABCG2, is a well… 
Highly Cited
2014
Highly Cited
2014
Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to Irinotecan
Colorectal cancer is the third most common cancer in the world. Despite surgery, up to 50% of patients relapse with incurable… 
2014
2014
The Use of Longitudinal 18F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts
Objectives Brain tumor imaging is challenging. Although 18F-FET PET is widely used in the clinic, the value of 18F-FET MicroPET… 
Highly Cited
2012
Highly Cited
2012
Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis.
Exogenous glucagon-like peptide-2 receptor (GLP-2R) activation elicits proliferative and cytoprotective responses in the… 
2010
2010
Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment
Purpose: Irinotecan (CPT11) treatment significantly improves the survival of colorectal cancer patients and is routinely used for… 
2008
2008
Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models
Purpose: In an attempt to identify genes that are involved in resistance to SN38, the active metabolite of irinotecan (also known… 
2008
2008
Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil.
BACKGROUND Use of irinotecan (CPT-11) as second-line therapy for metastatic colorectal cancer has shown some promise in cases… 
2006
2006
Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
The multigenic nature of drug response is increasingly recognized and underscores our current difficulties with adequately… 
2004
2004
Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma
A 55-year-old multiparous woman was diagnosed with stage IIIc ovarian clear cell carcinoma. Three years after the first surgery… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)